The early detection and diagnosis of cancer is critical to optimize the treatment and management of cancer patients. Typical methods such as imaging and tissue biopsy are invasive, time-consuming, and often imprecise. Thus, recent technological advances of dependable, facile, and minimally invasive collectible oncogenic biomarkers using human biofluids and secretions have been an active area of research. Recently, circulating long non-coding RNAs (lncRNAs) have been identified as promising biomarkers that fulfill many recommended properties of successful biomarkers for cancer diagnosis and prognosis. LncRNAs play essential roles in many cellular processes including DNA repair, cell proliferation, and epithelial-to-mesenchymal transition (EMT) by regulating the expression of various genes associated with cancer development and progression. Herein, we discuss the regulatory functions/pathways associated with multiple cancer-associated lncRNAs and their potential as prognostic/diagnostic markers for breast and cervical cancers. Additionally, we provide a correlation between lncRNA levels in the blood and clinicopathological data, including sensitivity, specificity, and Area Under Curve (AUC) merits of model performance value.

癌症的早期发现和诊断对于优化癌症患者的治疗和管理至关重要。诸如成像和组织活检之类的典型方法是侵入性的，费时的并且通常是不精确的。因此，使用人类生物流体和分泌物的可靠，简便和微创可收集的致癌生物​​标志物的最新技术进展一直是研究的活跃领域。最近，循环长非编码RNA（lncRNA）已被确认为有前途的生物标记，可以满足许多成功的生物标记用于癌症诊断和预后的推荐特性。LncRNA通过调节与癌症发生和发展相关的各种基因的表达，在许多细胞过程中起着至关重要的作用，包括DNA修复，细胞增殖以及上皮到间质转化（EMT）。在这里 我们讨论了与多种癌症相关的lncRNA相关的调控功能/途径及其作为乳腺癌和宫颈癌的预后/诊断标志物的潜力。此外，我们提供了血液中lncRNA水平与临床病理数据之间的相关性，包括敏感性，特异性和模型性能值的曲线下面积（AUC）优点。